This table shows the list known insiders, and is generated automatically from filings disclosed to the SEC. In addition to the names, most recent title, and director, officer, or 10% owner designation, we provide the latest disclosed holdings.
| Name | Shares | Options |
|---|---|---|
| Invus Public Equities, L.P. | 8,589,064 | 0 |
| BARRETT M JAMES See Note 1 | 4,995,664 | 0 |
| BARRIS PETER J See Note 1 | 4,995,664 | 0 |
| SANDELL SCOTT D See Note 1 | 4,995,664 | 0 |
| NEW ENTERPRISE ASSOCIATES 10 L P | 4,995,664 | 0 |
| BARRETT M JAMES See Note 3 | 4,481,758 | 0 |
| BARRIS PETER J See Note 3 | 4,481,758 | 0 |
| BARRETT M JAMES See Note 4 | 4,093,377 | 0 |
| BARRIS PETER J See Note 4 | 4,093,377 | 0 |
| NEW ENTERPRISE ASSOCIATES 13 LP | 4,093,377 | 0 |
| SANDELL SCOTT D See Note 4 | 4,093,377 | 0 |
| SANDELL SCOTT D See Note 2 | 2,730,334 | 0 |
| SANDELL SCOTT D See Note 3 | 2,237,196 | 0 |
| HENOS MICHAEL A By funds | 490,711 | 0 |
| HENOS MICHAEL A By fund | 469,454 | 0 |
| Magnani John L. | 366,078 | 0 |
| King Rachel K. | 356,064 | 21,000 |
| Rock Edwin | 310,000 | 0 |
| Thackray Helen M. | 148,615 | 0 |
| Johnson Bruce S | 138,980 | 0 |
| JUNIUS DANIEL M | 93,250 | 0 |
| Hahn Brian M. | 53,143 | 0 |
| Andrews Patricia S | 45,250 | 21,000 |
| Girard Armand | 29,161 | 0 |
| Semerjian Harout | 25,000 | 0 |
| PEARSON TIMOTHY R | 24,650 | 0 |
| HENOS MICHAEL A | 12,562 | 11,000 |
| Goldberg Mark Alan | 11,497 | 21,000 |
| King Rachel K. By The Rachel K. King 2013 GRAT | 0 | 0 |
| BARRETT M JAMES | 0 | 11,000 |
| HENOS MICHAEL A By Spouse | 0 | 0 |
| Gust William M. | 0 | 15,401 |
| BVF PARTNERS L P/IL | 0 | 0 |
| Jackson Scott Thomas | 0 | 21,000 |
| Baldwin John J. | 0 | 0 |
| King Rachel K. By Langley King 2013 GRAT | 0 | 0 |
| Feldman Eric Jay | 0 | 0 |
| LAMPERT MARK N | 0 | 0 |
| Koenig Scott | 0 | 21,000 |
| Magnani John L. By GlycoTech Corporation | 0 | 0 |
| Rath Chinmaya | 0 | 0 |
| Invus Public Equities Advisors, LLC | 0 | 0 |
| NEA PARTNERS 10 L P | 0 | 0 |
| Gust William M. By Anthem Capital | 0 | 0 |
| King Rachel K. By Spouse | 0 | 0 |
| Sanofi Via wholly-owned subsidiary, Genzyme Corp. | 0 | 0 |
| King Rachel K. By RBK LLC | 0 | 0 |
| TOP FRANKLIN H JR | 0 | 11,000 |
| HENOS MICHAEL A By Funds | 0 | 0 |
| King Rachel K. By Connor King 2013 GRAT | 0 | 0 |
| 0 | 0 | |
| King Rachel K. s | 0 | 0 |
While Insider sales are normal part of tax harvesting and is part of compensation of executives - A large number of transactions would indicate that the management isnt convinced that the price will go up and hence reducing their holding. This would be a possible indicator or fall in price
| Name | Shares | Price | Date |
|---|---|---|---|
| Hahn Brian M. | 3,700 | 1.95 | 2023 May 17 |
Insider buys arent usual, since it indicates a high conviction by the management that they believe the price will go up eventually. Usually a good sign that investors should consider this as a factor to purchase a stock, especially if the current SP is lower than the price the management bought these at. The table below doesnt include any Stock Options or RSUs. They're just open market purchases by the insiders.
| Name | Shares | Price | Date |
|---|---|---|---|
| JUNIUS DANIEL M | 30,000 | 1.56 | 2023 May 10 |
| Johnson Bruce S | 13,500 | 1.57 | 2023 May 08 |